Skip to main content
. 2018 Feb;9(1):170–179. doi: 10.21037/jgo.2017.06.10

Table 2. Open phase 2/3 studies for patients with MSS or MMR-p CRC.

Immune target Agent Phase Line NCT number
PD-1 Tremelimumab + durvalumab II Refractory NCT03007407
MEDI4736 + cediranib II Refractory NCT02484404
Nivolumab + TAS-102 II Refractory NCT02860546
PD-1/TLR Pembrolizumab + Poly-ICLC I/II Refractory NCT02834052

NCT, national clinical trial; PD-1, programmed cell death-1; TLR, toll-like receptor.